Cerenome, Inc. Common Stock (CNSY) Stock Price

CNSYStock
$1.70
Market Cap$12.90M
P/E—
PEG Ratio2.45
Div yield—
Beta2.39

CNSY Share Price Chart

Favorite Metrics

Price vs S&P 500 (4W)-9.20%
PEG Ratio2.45
VGM Score42.32

CNSY Earnings Surprise History

QuarterReport dateEPS estimateEPS actualSurprise
Q2 2026-$0.88-$1.31-48.86%(-$0.43)
Q1 2026-$0.87-$1.05-20.69%(-$0.18)
Q4 2025-$0.92$0.00+100.00%(+$0.92)
Q3 2025-$0.88-$1.00-14.29%(-$0.13)
Q2 2025-$3.25-$0.16+95.00%(+$3.09)

CNSY Analyst Recommendations

Jun 2026
Jul 2026
Aug 2026
Sep 2026
4.10
4.10
4.10
4.10

Industry Peers — Surgical & Medical Instruments(142)

SymbolValue ScoreGrowth ScoreMomentum ScoreP/S Ratio (TTM)Revenue Growth (5Y)Gross Margin (TTM)Operating Margin (TTM)Price
CNSYCerenome, Inc. Common Stock
——C3.1x——-628.1%$1.70
SYKStryker CorporationCBC4.4x11.8%65.3%21.3%$294.66
MMM3M CompanyCDB3.4x-5.0%39.4%18.4%$164.75
BSXBoston Scientific Corp.CBC3.1x15.2%69.5%19.8%$44.39
BDXBecton, Dickinson and Co.BDA2.5x6.3%46.7%9.6%$191.75
MDLNMedline Inc. Class A common stockCDC1.6x—26.2%6.0%$35.96
RMDResMed Inc.CCB5.9x12.1%61.1%33.4%$238.97
DXCMDexCom, Inc.CBB6.5x19.3%64.3%22.9%$86.04
WSTWest Pharmaceutical Services, Inc.DCA8.5x7.4%36.8%20.4%$384.02
SOLVSolventum CorporationCCB1.8x—54.8%23.9%$85.81
BAXBaxter International Inc.BDB1.1x-0.8%30.7%-2.3%$25.28

About Cerenome, Inc. Common Stock

Cerenome Inc is a CNS oncology company advancing an integrated platform that combines precision diagnostics, targeted therapeutics, and artificial intelligence to improve outcomes for patients with central nervous system cancers. The Company's CNSide Diagnostics platform supports the detection, molecular characterization, and longitudinal monitoring of CNS cancers through cerebrospinal fluid-based testing. Its therapeutic platform, REYOBIQ (rhenium Re186 obisbemeda), is being evaluated in clinical trials for leptomeningeal metastases, recurrent glioblastoma, and pediatric brain cancers. The data & artificial intelligence platform is designed to integrate diagnostic, molecular, imaging, and clinical data into actionable insights that support precision oncology and therapeutic innovation.